FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average b | ourden | | | | | | | | |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Kendall Keith J</u> | | | | | | 2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST] | | | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
|---|---|--|--|---------|---|---|--------------------------|-----------------------------|---|-------------------|------|--|---|---------------|--|---|---|--|--|--|--|--|--|
| | | | | | | rigassiro inciapoatios, me. [1701] | | | | | | | | | | X D | recto | .or | | 10% O | wner | | |
| , | | | | | - | | | | | | | | | | | | | (give title | | Other (| specify | | |
| (Last) | ` | , | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | | | De | elow) | - / | | below) | | | |
| C/O AQUESTIVE THERAPEUTICS, INC. | | | | | | 12/31/2019 | | | | | | | | | | CEO and President | | | | | | | |
| 30 TECHNOLOGY DRIVE | | | | | | | | | | | | | | | | | | | | | | | |
| (Street) | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| WARRE | N N. | J (| 07059 | | | | | | | | | | | | | X F | orm fi | led by One | e Rep | orting Perso | rting Person | | |
| | | | | | | | | | | | | | | | | | orm fi erson | | re tha | n One Repo | orting | | |
| (City) | (St | tate) (| (Zip) | | | | | | | | | | | | | | | | | | | | |
| | | Tab | le I - Nor | n-Deriv | ative | Sec | curitie | es Ac | qu | ired, | Disp | osed | of, o | r Ber | neficia | lly Ow | ned | | | | | | |
| 1. Title of Security (Instr. 3) | | | | | action | | | A. Deemed xecution Date. | | 3. Transaction | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, | | | | | | | | wnership n: Direct | 7. Nature of Indirect | | |
| Date (Month/D | | | | | | ar) i1 | if any (Month/Day/Yea | | Code | | | | Josed Of (D) (Instr. 3, | | | Ber | Beneficially Owned Following | | (D) or Indirect (I) (Instr. 4) | Beneficial Ownership | | | |
| | | | | | | (141 | | (MOIIIII/Day/Tea | | 0) | | | | (A) or | | Rep | Reported Transaction(s) | | (1) (111341. 4) | | (Instr. 4) | | |
| | | | | | | | | | | Code | ٧ | Amount | | (A) or (D) | Price | | | r. 3 and 4) | | | | | |
| Common Stock 12/31/ | | | | | |) | | | | M ⁽¹⁾ | | 329 |) A | | \$0 | | 662,985 | | | D | | | |
| Common Stock 12/3 | | | | | 1/2019 | 9 | | | | F ⁽²⁾ | | 329 | 9 D | | \$5.8 | 2 662,656 | | ,656 | D | | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | | | | |
| (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Day | Date, | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisat Expiration Date (Month/Day/Year | | | | 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4) | | 14) | 8. Price Derivat Securit (Instr. § | ive y) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | Own Forn Direc or In (I) (Ir | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exe | e ercisable | | piration ite | Title | | Amount or Number of Shares | | | | | | | | |
| Restricted Stock | \$0 | 12/31/2019 | | | M ⁽¹⁾ | | | 329 | 12/ | /31/2019 | | (3) | Com | mon | 329 | \$0 | | 662 | | D | | | |

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- 3. There are no expiration dates on RSUs.

Remarks:

/s/ Robert Arnold, as Attorney- 01/02/2020 In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.